Barclays analyst Andrew Mok raised the firm’s price target on Universal Health to $189 from $181 and keeps an Equal Weight rating on the shares post the Q1 report. The company posted broad pricing strength and strong acute inpatient volumes, which drove a big EBITDA beat, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health reports Q1 adjusted EPS $3.70 vs. $2.34 last year
- UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2024 FIRST QUARTER FINANCIAL RESULTS
- Universal Health reports Q1 adjusted EPS $3.70, consensus $3.16
- Notable companies reporting after market close
- UHS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
